The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer
about
Combinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current statusAddition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohortManagement of recurrent epithelial ovarian cancer.Repurposing Drugs in Oncology (ReDO)-itraconazole as an anti-cancer agent.Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter studyBevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancerClinical response in patients with ovarian cancer treated with metronomic chemotherapy.Metronomics as maintenance treatment in oncology: time for chemo-switch.Metronomics: towards personalized chemotherapy?Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments.Maintenance treatment with oral cyclophosphamide and bevacizumab in patients with recurrent epithelial ovarian cancer.Metabolic behavior prediction of pazopanib by cytochrome P450 (CYP) 3A4 by molecular docking.Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2Immunological Mechanisms of Low and Ultra-Low Dose Cancer Chemotherapy.Radiotherapy-assisted tumor selective metronomic oral chemotherapy.Metronomic Four-Drug Regimen Has Anti-tumor Activity in Pediatric Low-Grade Glioma; The Results of a Phase II Clinical Trial
P2860
Q27001560-CD2C3512-70B5-4DAA-B3F2-132C390E77FFQ33422577-AB0A8EDC-C1A3-473A-8573-648E2AB0175AQ34070046-DBF6DC7B-FC5E-493A-8F9D-78683E24612CQ34474583-D0713DC4-1637-42EB-A973-E08087F0FD21Q34993605-1099FE49-A6B4-4398-B9DF-B9D7EE903531Q37022497-70D2DBD7-2BBC-48F4-B248-0F01CC6EEE94Q37679904-5999A641-F623-47AB-BD87-2DFB1B5A7150Q37707573-CE665B54-34BE-4E23-9F99-E8509460905EQ38218923-4214E6E2-8DEF-4A89-A1A0-4E8359415311Q38524502-55B2C634-4E21-4266-A5A4-EBBE184637BDQ38969949-1FC014A2-B8F0-4C89-AD11-4BBB7D8DB2FBQ41304112-820E6664-75D5-4BCF-93D3-4E4162E2A582Q42037461-D4EC3A40-EE8C-4259-8074-C9772C8B9E24Q42701148-940BA807-FF1D-4009-8269-A16444A54077Q48247510-87C56DD2-BA50-4C82-8456-95363D8CC8C4Q57490984-97836EAB-67A7-4267-96CA-8F2539FA46EA
P2860
The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The combination of intravenous ...... stant recurrent ovarian cancer
@en
The combination of intravenous ...... tant recurrent ovarian cancer.
@nl
type
label
The combination of intravenous ...... stant recurrent ovarian cancer
@en
The combination of intravenous ...... tant recurrent ovarian cancer.
@nl
prefLabel
The combination of intravenous ...... stant recurrent ovarian cancer
@en
The combination of intravenous ...... tant recurrent ovarian cancer.
@nl
P2093
P2860
P1476
The combination of intravenous ...... stant recurrent ovarian cancer
@en
P2093
Alfred Rademaker
Emese Zsiros
Emma L Barber
John R Lurain
Julian C Schink
Nikki L Neubauer
P2860
P304
P356
10.3802/JGO.2013.24.3.258
P577
2013-07-04T00:00:00Z